5637-luc Orthotopic Mouse Model Service for Bladder Cancer

The 5637-luc orthotopic mouse model offers a well-characterized platform for investigating non-muscle-invasive urothelial carcinoma biology and intravesical therapeutic efficacy within the authentic architecture of the urinary bladder. Alfa Cytology constructs, validates, and manages this luciferase-enabled orthotopic system under stringent preclinical standards, supplying researchers with reproducible tumor kinetics and quantitative imaging endpoints to advance their early-stage oncology portfolios.

Overview of 5637-luc Orthotopic Mouse Model for Bladder Cancer

The 5637-luc orthotopic xenograft model is generated by delivering luciferase-expressing 5637 human bladder carcinoma cells into the murine bladder lumen via transurethral catheterization, creating a tumor that develops on the urothelial surface in direct contact with urine and the underlying lamina propria. Because the cells are introduced into their natural anatomical niche, the resulting lesion recapitulates the superficial growth pattern, stromal engagement, and microenvironmental cues typical of human non-muscle-invasive transitional cell carcinoma far more faithfully than ectopic implantation approaches. The integrated firefly luciferase reporter permits serial, non-invasive quantification of tumor burden through bioluminescence imaging, yielding a sensitive metric for tracking engraftment success, exponential outgrowth, and therapy-induced regression without the need for repeated cohort sacrifice.

Fig 1. Expression (qPCR), cell localization (FISH, 5637 and T24) and immunofluorescence of LINC00612 in various bladder cancer cell lines. (Miao, Liying, et al., 2019)

Histologically, 5637-derived orthotopic tumors display papillary and flat urothelial morphology with moderate nuclear atypia, consistent with the grade II origin of the parental cell line. The model is further distinguished by the cell line's documented secretion of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, which introduces a unique cytokine milieu that may influence immune cell recruitment, stromal remodeling, and drug penetration dynamics within the bladder wall. These characteristics make the 5637-luc orthotopic system particularly suited for evaluating intravesical delivery platforms, bacillus Calmette-Guérin-like immunomodulators, and chemotherapeutic agents in a setting that preserves the barrier function and luminal chemistry of the intact urinary bladder.

Cell Line Information: 5637-luc

5637-luc is a luciferase-reporter derivative of the 5637 human bladder cancer cell line, engineered through lentiviral transduction to stably express firefly luciferase for in vivo bioluminescent tracking. The parental 5637 line was established from a grade II transitional cell carcinoma of the urinary bladder in a 68-year-old Caucasian male and has been extensively utilized as a representative model of non-muscle-invasive urothelial carcinoma with luminal-papillary molecular features. Key characteristics are summarized below:

Our Services

Alfa Cytology offers comprehensive 5637-luc orthotopic model services spanning feasibility assessment, surgical model construction, longitudinal bioluminescence imaging, and detailed histopathological endpoint analysis. Every study is conducted within fully accredited vivarium facilities under IACUC oversight, ensuring scientific rigor, ethical compliance, and complete data traceability from pilot through final report.

Workflow of 5637-luc Orthotopic Mouse Model Construction

Construction of the 5637-luc orthotopic bladder cancer model follows a refined intravesical instillation protocol optimized for consistent engraftment, minimal procedural morbidity, and reproducible superficial tumor growth. The procedure integrates bladder preconditioning, controlled cell delivery, and longitudinal bioluminescence monitoring, as detailed below:

1. Cell Preparation and Batch Validation: 5637-luc cells are expanded under low-passage conditions (passage 3–6) in complete antibiotic-free medium to preserve differentiation status and tumorigenic potential. Viability is confirmed by trypan blue exclusion (>95% required), and luciferase expression is quantified via in vitro bioluminescence assay to verify uniform reporter signal intensity across the batch.
2. Animal Selection and Acclimation: Female athymic nude mice (6–8 weeks old) are selected based on anatomical suitability for transurethral catheterization. A one-week acclimation period is observed under pathogen-free housing, with daily health checks and body weight recording to establish individual baseline parameters.
3. Anesthesia and Bladder Preparation: Mice are anesthetized with isoflurane (3% induction, 1.5–2% maintenance) and placed supine on a thermally regulated surgical platform. The bladder is gently emptied by manual abdominal compression to create a receptive lumen for subsequent instillation.
4. Transurethral Catheterization: A sterile 24-gauge pediatric venous catheter, lubricated with non-irritating gel, is advanced transurethrally into the bladder under aseptic technique. Correct positioning is confirmed by visual inspection and gentle resistance at the bladder neck, avoiding trauma to the urethral mucosa or trigone.
5. Bladder Mucosal Preconditioning: The urothelial glycosaminoglycan layer is pretreated with 50 µL of 0.1% poly-L-lysine instilled slowly over 100 seconds to prevent vesicoureteral reflux. The solution is retained for 15–20 minutes to enhance electrostatic adhesion of tumor cells to the bladder wall before gentle evacuation.
6. Tumor Cell Instillation: 5637-luc cells (3 × 10⁶) in 50 µL PBS are slowly instilled at 10 µL per 20 seconds to avoid reflux and ensure uniform distribution across the bladder mucosal surface. A single-cell suspension is essential to prevent clumping and achieve consistent seeding.
7. Retention and Recovery: The urethral meatus is lightly clamped to prevent retrograde leakage, and cells are retained in the bladder for 1.5 hours under continuous anesthesia with thermal support. Afterward, the clamp and catheter are removed, the bladder is allowed to empty spontaneously, and mice recover in a heated chamber until normal micturition and mobility are restored.
8. Bioluminescence Imaging and Growth Monitoring: Beginning at day 7–10 post-implantation, tumor establishment and expansion are monitored via IVIS Spectrum or equivalent bioluminescence imaging system following intraperitoneal D-luciferin injection (150 mg/kg). Regions of interest are defined around the bladder region, and photon flux (photons/sec/cm²/sr) is quantified to generate longitudinal growth curves for each animal.
9. Endpoint Analysis and Tissue Processing: At study termination, mice are humanely euthanized and bladders are excised, weighed, and processed for formalin-fixed paraffin embedding. Serial sections are stained with H&E for morphological assessment, and immunohistochemistry is performed for Ki67, human-specific cytokeratins, and CD44 to confirm tumor origin, proliferative activity, and phenotypic fidelity.

Fig 2. 5637-luc Orthotopic Mouse Model construction workflow.

Case Study-5637-luc Orthotopic Mouse Model Development

In a representative preclinical program, the 5637-luc orthotopic model was employed to assess the efficacy of a novel intravesical agent designed to disrupt urothelial tumor-stroma interactions in non-muscle-invasive bladder cancer. Following successful engraftment confirmed by bioluminescence imaging within the first two weeks, cohorts were randomized to receive either the investigational compound or vehicle control via intravesical instillation. Longitudinal BLI revealed differential growth trajectories between treatment arms, with the active compound cohort showing attenuated photon flux accumulation relative to controls. Terminal histopathology demonstrated reduced tumor burden, diminished mucosal invasion depth, and lower Ki67 proliferation indices in treated animals, while preserving overall bladder wall architecture in responders. These preclinical observations informed the compound's mechanism-of-action hypothesis and supported progression toward subsequent IND-enabling pharmacology and toxicology studies.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your 5637-luc orthotopic bladder cancer model program provides access to a scientifically driven, quality-centric preclinical infrastructure engineered to de-risk therapeutic development. Our core differentiators include:

• Specialized expertise in urothelial oncology models, with optimized intravesical protocols that yield consistent engraftment and physiologically relevant superficial tumor growth in the native bladder environment.
• Integrated bioluminescence imaging platforms enabling non-invasive, quantitative longitudinal tracking of individual tumor dynamics without introducing serial sacrifice artifacts into your dataset.
• Rigorous cell line authentication and quality control, encompassing STR profiling, mycoplasma screening, and luciferase expression validation to ensure model fidelity and batch-to-batch reproducibility.
• Adaptable study architectures supporting single-agent screening, combination intravesical regimens, drug delivery vehicle optimization, and pharmacodynamic biomarker evaluation tailored to your therapeutic modality.
• Comprehensive endpoint capabilities including digital histopathology, immunohistochemistry, multiplex immunofluorescence, and cytokine profiling to generate mechanistic insights alongside standard efficacy readouts.
• Dedicated scientific project management providing transparent milestone reporting, timeline accountability, and direct consultation from protocol design through final data package delivery.

Contact Us

Whether your program targets non-muscle-invasive bladder cancer with an intravesical immunotherapy, a novel chemotherapy formulation, or a stromal-disrupting small molecule, Alfa Cytology is equipped to accelerate your preclinical development with our 5637-luc orthotopic model expertise. Reach out to us today to discuss your study design, review our capabilities, and receive a customized proposal aligned with your scientific objectives and timeline. Our team looks forward to partnering with you to generate the robust, translationally relevant data your pipeline requires.

For research use only. Not intended for any clinical use.